Dorzolamide: Nursing Drug Guide, Sulfonamide Sensitivity & Eye Drop Safety
Screen sulfonamide allergy before the first drop, teach three-times-daily scheduling with contamination-free technique, hold when creatinine clearance is below 30 mL/min, and monitor for systemic hypersensitivity despite topical use.
Dorzolamide is a sulfonamide carbonic anhydrase inhibitor. Although given as an eye drop, it is absorbed systemically, so sulfonamide-type reactions—including serious hypersensitivity—can occur. Fatalities have been reported rarely with sulfonamides. Nurses must confirm allergy history, teach strict dropper hygiene (tip never touches eye, lashes, or fingers), reinforce one drop three times daily, and hold when CrCl <30 mL/min per labeling. Escalate urgently for Stevens-Johnson syndrome–type rash, bronchospasm, or anaphylaxis symptoms.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first instillation, confirm no sulfonamide hypersensitivity, verify renal function is not severely impaired, teach TID timing with five-minute spacing from other eye drops, and demonstrate sterile technique so the bottle tip never contaminates. Document bitter-taste counseling and contact-lens timing.
Most common brand names
Dorzolamide hydrochloride ophthalmic solution 2% is marketed as TRUSOPT and is combined with timolol in COSOPT (dorzolamide 2% / timolol 0.5%). Always match the product to the order—fixed combinations are not interchangeable with dorzolamide alone.
Regimens often include other IOP-lowering agents such as latanoprost or brimonidine; separate each topical ophthalmic drug by at least five minutes per prescribing information.
Why we give it — Indications
Dorzolamide is indicated for elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Nursing focus is sulfonamide safety screening, TID adherence, renal clearance review, and coordination with ophthalmology for pressure targets.
| Use | Detail |
|---|---|
| Open-angle glaucoma / ocular hypertension | Lowers IOP by decreasing aqueous humor secretion via carbonic anhydrase inhibition in the ciliary processes |
| Adjunctive topical therapy | May be used with other topical ophthalmic agents; wait at least five minutes between different drops |
| Acute angle-closure glaucoma | Requires additional therapeutic interventions beyond ocular hypotensive agents alone per labeling |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Carbonic anhydrase catalyzes hydration of carbon dioxide and dehydration of carbonic acid. In the ciliary processes, inhibition reduces bicarbonate formation, sodium transport, and fluid secretion into aqueous humor, lowering intraocular pressure. Dorzolamide is a topical sulfonamide inhibitor of carbonic anhydrase II; despite ocular administration, drug reaches the systemic circulation and red blood cells during chronic dosing.
Dosing overview
The dose is one drop in the affected eye(s) three times daily. Efficacy when dosed less frequently than three times daily has not been established.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| IOP lowering | Approximately 3–5 mmHg throughout the day in clinical studies | Requires consistent TID dosing; less-than-TID schedules are not established as effective |
| Systemic absorption | Reaches systemic circulation after topical dosing; accumulates in RBCs with chronic use | Explains sulfonamide risk and renal excretion considerations despite topical route |
| Plasma levels | Often below assay quantitation (15 nM) after topical use | Clinical monitoring focuses on ocular tolerance, renal function, and allergy—not serum drug levels |
| Elimination | Primarily unchanged in urine; RBC washout half-life about four months after stopping | Reinforce renal hold rules and avoid duplicate oral carbonic anhydrase inhibitors |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Screen for sulfonamide or drug hypersensitivity and prior serious reactions to any sulfonamide product
- Review renal function—serum creatinine and estimated clearance; hold discussion when chronic kidney disease is severe (CrCl <30 mL/min)
- Perform medication reconciliation for oral carbonic anhydrase inhibitors, high-dose aspirin, and other topical glaucoma drops
- Order basic metabolic panel when renal status is uncertain before starting or continuing therapy
Contraindications
- Hypersensitivity to any component of the product (including sulfonamide sensitivity per warnings)
Important interactions
| Agent / factor | Effect | Nursing action |
|---|---|---|
| Oral carbonic anhydrase inhibitors | Additive systemic carbonic anhydrase inhibition—not recommended concomitantly | Reconcile home and MAR entries; notify prescriber/pharmacist if both are ordered |
| High-dose salicylate therapy | Potential acid-base and electrolyte disturbances similar to oral CA inhibitors | Flag aspirin or salicylate therapy; monitor per prescriber when both are necessary |
| Soft contact lenses | Benzalkonium chloride may absorb into lenses | Remove lenses before instillation; reinsert 15 minutes after dosing |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Topical ophthalmic solution 2%. Follow medication administration rights and institutional eye care protocols when teaching or supervising instillation.
- Wash hands; remove contact lenses; tilt head back, pull down lower lid, instill one drop without allowing the dispenser tip to contact the eye, eyelid, lashes, fingers, or any surface
- Close the eye gently; optional punctal occlusion per local protocol may reduce systemic absorption
- Administer on a three-times-daily schedule; if using multiple topical agents, wait at least five minutes between different drops
- Replace cap immediately; store at 20°C to 25°C (68°F to 77°F); protect from light; may use until expiration date on bottle after opening per label
Bacterial keratitis has been reported with contaminated multidose topical ophthalmic containers, especially when the ocular surface is compromised. Instruct patients never to share bottles and to discontinue use if the tip contacts the eye or surrounding structures. Serious eye damage and vision loss may result from contaminated solutions.
Expected therapeutic response
- Gradual intraocular pressure reduction on ophthalmology tonometry—clinical studies report approximately 3–5 mmHg lowering with TID dosing
- Stable vision without new progressive vision changes beyond expected transient stinging or bitter taste
- Patient demonstrates TID technique, five-minute spacing from other drops, and understanding of sulfonamide warning signs
Red flags — Stop and act
Hold the drop and escalate when systemic sulfonamide reactions or serious ocular events occur. Contact local poison control or toxicology services per facility protocol for suspected overdose.
- Serious sulfonamide reactions—Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, blood dyscrasias, or systemic hypersensitivity with bronchospasm or angioedema
- Severe or worsening eye pain, purulent discharge, or corneal opacity suggesting keratitis
- Acute blurred vision or field loss distinct from mild expected irritation
- Persistent conjunctivitis or lid reactions with allergic appearance—discontinue and evaluate before restart per labeling
- Suspected bottle contamination, missed renal hold (CrCl <30), or concomitant oral carbonic anhydrase inhibitor without prescriber plan
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Ocular burning, stinging, discomfort | Most common—approximately one-third immediately after instillation | Differentiate expected irritation from pain, discharge, or vision change; document and notify if severe |
| Bitter taste | Approximately one-quarter of patients | Teach punctal occlusion or gentle lid closure; reassure if otherwise well |
| Superficial punctate keratitis | 10–15% in trials | Coordinate ophthalmology review; assess technique and corneal health |
| Ocular allergic reaction / conjunctivitis | Approximately 10%; may resemble allergic-type lid reactions | Discontinue per labeling; do not restart without prescriber evaluation |
| Eye redness, tearing, dryness, photophobia | Reported in 1–5% | Rule out contamination; notify prescriber if vision affected |
| Headache, nausea, fatigue | Infrequent systemic reports | Assess renal function and concomitant CA inhibitors; escalate if worsening |
On a small screen, swipe or scroll sideways to see the full table.
Overdose and toxicity
Topical overdose may contribute to electrolyte imbalance, acidotic state, and possible central nervous system effects per labeling. Monitor serum electrolytes (particularly potassium) and blood pH when systemic toxicity is suspected. Antidote: Not specified in the reviewed prescribing information.
If multiple extra drops are instilled, monitor for ocular irritation and systemic symptoms; notify prescriber/pharmacist and follow local poison control / toxicology guidance per facility protocol—do not rely on country-specific emergency numbers in patient-facing teaching.
Look-alike / sound-alike and error prevention
- Dorzolamide vs brinzolamide vs acetazolamide—all carbonic anhydrase inhibitors; verify generic name and route (topical vs oral)
- TRUSOPT vs COSOPT—COSOPT contains timolol; beta-blocker precautions apply to the combination product
- TID dorzolamide vs QHS prostaglandin analog—patients may confuse schedules when using multiple glaucoma bottles
- Right eye vs left eye—document affected eye(s) on the MAR
- Shared household bottles—each patient needs a dedicated dispenser to prevent cross-contamination
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Timing | Three times daily—efficacy below TID is not established |
| Sulfonamide history | Ask about sulfa antibiotics, diuretics, and prior reactions before first dose |
| Renal hold | Not recommended when CrCl <30 mL/min—confirm labs with pharmacy |
| Contact lenses | Remove before drop; wait 15 minutes before reinserting soft lenses |
| Multiple drops | Wait at least five minutes between different topical ophthalmic agents |
| Commonly missed | Bitter taste teaching, sulfonamide warning signs, and duplicate oral CA inhibitor on home list |
| Ask pharmacy when | CrCl near 30, overlapping CA inhibitors, or suspected bottle contamination |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Severe renal impairment (CrCl <30 mL/min) | Not recommended—drug and metabolite excreted predominantly by kidney |
| Hepatic impairment | Not studied—use with caution per labeling |
| Low corneal endothelial cell count | Increased risk of corneal edema—use caution |
| Prior sulfonamide reaction | Sensitization may recur regardless of route—avoid unless specialist directs |
| Pediatric patients | Safety and effectiveness demonstrated in a 3-month pediatric trial—still counsel caregivers on TID technique and allergy signs |
| Pregnancy / lactation | No adequate human studies; balance clinical need with potential fetal/infant exposure—see LactMed in references |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Intraocular pressure per ophthalmology schedule; symptom review for stinging, bitter taste, and vision changes
- Renal function when starting or continuing in patients with kidney disease risk
- Signs of sulfonamide hypersensitivity, ocular allergic reactions, and corneal infection—especially after technique lapses
Document
- Sulfonamide allergy screen, affected eye(s), TID schedule, and five-minute spacing teaching
- Demonstration of instillation without tip contamination; patient/caregiver teach-back
- Adverse effects reported and prescriber/pharmacist notifications
Patient teaching
- This drop contains a sulfonamide medicine absorbed into the body—tell your care team about any sulfa allergy and stop the drop for serious rash, swelling, or breathing difficulty
- Use exactly one drop in the affected eye(s) three times daily on a regular schedule
- Do not let the bottle tip touch your eye, fingers, or any surface; replace the cap immediately
- A bitter taste is common—closing your eye gently after the drop may help
- Remove soft contact lenses before the drop and wait 15 minutes before putting them back in
- Wait at least five minutes between different eye medications
- Contact your eye care team promptly for eye pain, sudden vision change, discharge, or worsening redness
The Hold Rule
Do not instill and contact the prescriber or pharmacist when:
- Known hypersensitivity to dorzolamide, sulfonamides, or any formulation ingredient
- Severe renal impairment (CrCl <30 mL/min) unless specialist directs otherwise with monitoring
- Concomitant oral carbonic anhydrase inhibitor without a coordinated prescriber plan
- Signs of serious sulfonamide reaction, Stevens-Johnson syndrome, or systemic allergy
- Suspected bottle contamination or active bacterial keratitis pending ophthalmology review
- Persistent allergic conjunctivitis or lid reaction—discontinue until evaluated per labeling
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Glaucoma regimens fail when sulfonamide risks are missed, TID schedules slip to twice daily, or bottle tips contaminate multidose containers. Build renal screening and allergy history into the first teaching visit alongside drop spacing and bitter-taste expectations.
1. Check-before-you-give protocol
- Right patient, drug, eye(s), dose (one drop), route, and TID time
- Confirm no sulfonamide contraindication and CrCl is not below 30 mL/min
- Verify spacing from other topical eye drops and contact lenses removed
- Observe or teach instillation without dropper-tip contamination
2. High-alert and safety badge
Not a traditional high-alert medication, but systemic sulfonamide absorption and keratitis risk require proactive screening and teachingTreat the first dose like a safety briefing: document sulfonamide allergy screen, renal review, TID schedule, and contamination prevention before the patient leaves with the bottle.
3. Clinical workflow: hold and question rules
- If the patient uses the drop only twice daily, reinforce TID timing and clarify with pharmacy—less-than-TID efficacy is not established
- If the bottle tip touched the eye or counter, counsel on contamination risk and ask pharmacy whether replacement is needed per policy
- Escalate same-day for serious rash, bronchospasm, acute vision loss, or keratitis signs—do not wait for routine follow-up
4. Critical teach-back questions
- “What allergy history must we know before this drop?” (Patient should mention sulfonamide/sulfa reactions and report rash or breathing problems.)
- “How many drops and how often each day?” (Patient should state one drop three times daily—not once daily or twice daily.)
5. Care coordination
Pharmacist: Reconcile topical and oral carbonic anhydrase inhibitors, renal dosing, salicylate interactions, and duplicate glaucoma therapy
Ophthalmology / prescriber: Notify for suspected sulfonamide reaction, allergic conjunctivitis, inadequate IOP control despite TID adherence, or corneal edema concerns
🧠 Quick mental checklist
- Did I screen sulfonamide allergy and check CrCl is not below 30 mL/min?
- Is the order one drop three times daily—not BID or QHS only?
- Did the dropper tip stay sterile with no contact to eye, lashes, or fingers?
- Are other topical eye drops spaced at least five minutes apart?
- Did I teach bitter taste, contact-lens timing, and when to stop for rash or breathing problems?
Dorzolamide NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for dorzolamide using a tabbed outpatient glaucoma case (MAR, labs, history, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, administration safety, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Dorzolamide 2% — 1 drop both eyes TID (0800, 1400, 2200)
- Timolol 0.5% — 1 drop both eyes BID (0800, 2000)
- Latanoprost 0.005% — 1 drop both eyes QHS
- 1400: patient missed morning dorzolamide; asks nurse to give two drops now to catch up
- Serum creatinine 2.1 mg/dL (baseline 1.0 six months ago)
- eGFR 28 mL/min/1.73 m² (calculated today)
- BMP otherwise: K 4.2 mEq/L, HCO₃ 22 mEq/L
- IOP clinic (last week): OD 22 mmHg, OS 21 mmHg on current regimen
- 72-year-old with primary open-angle glaucoma and stage 4 chronic kidney disease
- History of hives with sulfamethoxazole five years ago—listed as allergy
- Home acetazolamide 250 mg PO BID started two weeks ago by ophthalmology—continues on MAR
- Wears soft contact lenses; reports bitter taste after every dorzolamide dose
- 1350: Mild conjunctival injection; denies eye pain; vision unchanged
- 1410: Patient instilled drops with bottle tip touching upper eyelid; cap replaced without cleaning
- 1420: Reinforced TID schedule, five-minute spacing, and sulfonamide warning signs
Answer key & rationale
Frequently asked questions
Why is dorzolamide considered a sulfonamide risk even though it is an eye drop?
Dorzolamide is a sulfonamide absorbed systemically after topical administration. The same types of adverse reactions attributable to sulfonamides may occur, including serious hypersensitivity. Nurses must screen allergy history and teach patients to stop the drop and seek urgent care for severe skin reactions or systemic allergy signs.
How often should dorzolamide be instilled?
The dose is one drop in the affected eye(s) three times daily. Efficacy when dosed less frequently than three times daily has not been established. If more than one topical ophthalmic drug is used, administer agents at least five minutes apart.
When should dorzolamide be held for kidney function?
Dorzolamide has not been studied in severe renal impairment (creatinine clearance below 30 mL/min). Because the drug and its metabolite are excreted predominantly by the kidney, ophthalmic dorzolamide is not recommended in such patients.
Can dorzolamide be used with oral carbonic anhydrase inhibitors?
Concomitant administration of topical dorzolamide and oral carbonic anhydrase inhibitors is not recommended because of potential additive systemic carbonic anhydrase inhibition.
What is the most common patient-reported effect after dorzolamide?
Ocular burning, stinging, or discomfort immediately after instillation occurs in approximately one-third of patients. About one-quarter note a bitter taste after administration.
References
-
U.S. National Library of Medicine. Dorzolamide hydrochloride ophthalmic solution 2% — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8417d162-65a1-4266-bca7-707af1193bf3
-
Drugs and Lactation Database (LactMed). Dorzolamide. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM98/
-
National Institute for Health and Care Excellence. Glaucoma: diagnosis and management (NG81).https://www.nice.org.uk/guidance/ng81
-
National Eye Institute. Glaucoma. NIH.https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma
-
U.S. Food and Drug Administration. What You Should Know about Eye Drops.https://www.fda.gov/drugs/buying-using-medicine-safely/what-you-should-know-about-eye-drops
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.